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Abstract
We propose new summary measures of diagnostic test accuracy which can be used as companions
to existing diagnostic accuracy measures. Conceptually, our summary measures are tantamount to the
so-called Hellinger affinity and we show that they can be regarded as measures of agreement constructed
from similar geometrical principles as Pearson correlation. A covariate-specific version of our summary
index is developed, which can be used to assess the discrimination performance of a diagnostic test,
conditionally on the value of a predictor. Nonparametric Bayes estimators for the proposed indexes
are devised, theoretical properties of the corresponding priors are derived, and the performance of our
methods is assessed through a simulation study. Data from a prostate cancer diagnosis study are used
to illustrate our methods.
Keywords: Covariate-specific diagnostic; Hellinger affinity; Medical diagnostic test; Nonparametric
Bayes; Summary measure.
1 Introduction
Accurate diagnosis is a key target of diagnostic decision-making. Before a medical diagnostic test is
routinely applied in practice, it is important to evaluate its performance in discriminating between diseased
and non-diseased subjects. The most well-known summary accuracy measures are the AUC (Area Under
the receiver operating characteristic Curve) and the Youden index (Youden, 1950); other summary indexes
can be found in Pepe (2003, Section 4.3.3). These well-known summary measures at times gloss over
important differences between diseased and non-diseased subjects. To see when this might happen let
YD ∼ FD and YD¯ ∼ FD¯ denote the test results for diseased and non-diseased subjects. Formally, the AUC
consists of P (YD > YD¯) and it is typically argued that AUC = 0.5 for a test that does no better than
chance in discriminating between diseased and non-diseased individuals, while AUC = 1 for a test that
perfectly distinguishes between diseased and non-diseased subjects. While AUC is widely used in practice,
Figure 1 illustrates a setting under which the AUC is known to perform poorly. Regarding this setting,
Lee and Hsiao (1996) make the following comment:
“For the two populations of the diseased and the non-diseased [...] the marker perfectly separates
the two. Therefore, any clinician (or epidemiologist) will have no trouble in choosing a decision
rule for the marker, that is, high and low cutoff points. Nevertheless, adopting the AUC as
the measure of overall performance leads one to conclude that the marker is not better than
flipping a fair coin (its AUC is 0.5) ”
Throughout, we will refer to the situation in Figure 1 as the ‘separation trap,’ since one has perfect
discrimination but AUC = 0.5. As can be seen from Figure 1, even though the populations of diseased
and non-diseased subjects are perfectly separated, half of the diseased-subjects are predicted to have a test
result higher than the non-diseased subjects, and thus AUC = 0.5.
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Figure 1: The separation trap: Perfect discrimination but AUC = 0.5. Details on the truncated normal densities
used to construct this example can be found in Example 2; the black and grey lines respectively denote the densities
of the biomarkers of the diseased and non-diseased subjects.
But beyond the AUC, the Youden index (YI) also falls into the separation trap. To see this recall that
YI = maxc∈R {FD¯(c)− FD(c)}, with YI = 0 corresponding to complete overlap (FD¯(c) = FD(c)), and it is
often argued that YI = 1 when the distributions are ‘completely separated’. It is straightforward to show
that in the example in Figure 1, it holds that YI = 1/2, while the distributions of the markers for diseased
and non-diseased subjects are completely separated—thus confirming that the Youden index would fall
into the separation trap. The optimal cutoff region yielded through the Youden index is
arg max
c∈R
{FD¯(c)− FD(c)} = [2, 4].
Interestingly, however, the more sensible cutoff region [−4,−2]∪[2, 4] could have been obtained by adjusting
the definition of Youden index to consider the absolute value of the difference between distribution functions,
but even this modified index would be equal to 1/2.
A main goal of this article is to propose new diagnostic accuracy measures that accommodate the
separation trap and that can be used as companions, or possibly as alternatives, to existing diagnostic
accuracy measures. Conceptually, our summary measures can be motivated by first considering a geometric
interpretation of covariance and Pearson correlation. By recalling the well-known fact that for zero-mean
finite-variance random variables X and Y , the covariance can be interpreted as an inner product between
random variables (Williams, 1991), it follows that Pearson correlation
ρ =
cov(X,Y )
sd(X)sd(Y )
= cos(X∠Y ), (1)
can be interpreted as a cosine of the angle between X and Y . This simple geometric interpretation is
handy for understanding some basic properties of the Pearson correlation, including the fact that just like
a cosine, ρ is between -1 and 1, and that orthogonality in such context corresponds to the case where there
is no agreement between X and Y , that is, cov(X,Y ) = 0. The summary measures we develop, introduced
in Section 2, are constructed along the same lines, but are based on evaluating the level of agreement
between densities (of the biomarkers of diseased and non-diseased subjects) instead of focusing on random
variables—as Pearson correlation does.
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A covariate-specific version of our main summary index is here devised, which can be used to assess the
discrimination performance of a diagnostic test, conditionally on the value of a covariate. Nonparametric
Bayesian estimators for all proposed indexes are developed and the numerical performance of a specific
implementation is evaluated in detail through a simulation study. Using Bayesian nonparametric (BNP)
inference in a medical diagnostic setting is not unprecedented (Erkanli et al , 2006; Gu et al , 2008; Ina´cio
de Carvalho et al , 2013; Rodriguez and Martinez, 2014; Ina´cio de Carvalho et al , 2015; Branscum et al ,
2015; Johnson and de Carvalho, 2015; Ina´cio de Carvalho et al , 2016), and doing so provides a great deal
of flexibility particularly in the dependent case (i.e., a covariate is present). An additional computational
advantage of our covariate-specific summary measure with respect to that of Ina´cio de Carvalho et al
(2013) is that it avoids the need of computing conditional quantiles over a grid of covariates—a task which
requires a substantial computational investment. More importantly, as we elaborate below, our summary
measures do not fall into the separation trap depicted in Figure 1.
The article is organized as follows. In the next section we introduce the proposed measures along
with the corresponding inference tools. In Section 3 we conduct a simulation study. Section 4 offers an
illustration of our methods in a prostate cancer diagnosis case study. Proofs are included in the online
supplementary materials.
2 Geometric measures of diagnostic test accuracy
2.1 Angle-based summary measures of diagnostic test accuracy
Our summary measures are built on similar construction principles as Pearson correlation, but instead of
looking at the angle between random variables as in (1), we work directly with the density of the biomarker
outcome for diseased and non-diseased subjects, which we denote as fD and fD¯, respectively. Thus, in
place of the covariance inner product we use 〈fD, fD¯〉 =
∫∞
−∞ fD(y)fD¯(y) dy, and in place of the standard
deviation (sd) norms, we use ‖fD‖ = {
∫∞
−∞ f
2
D(y) dy}1/2 < ∞, and ‖fD¯‖ = {
∫∞
−∞ f
2
D¯
(y) dy}1/2 < ∞. The
starting point for the construction of our measure is given by the following standardized inner product:
κ¯ =
〈fD, fD¯〉
‖fD‖‖fD¯‖
. (2)
For a medical test with perfect discriminatory ability we would have κ¯ = 0, as fD would be orthogonal
to fD¯. The higher the value of κ¯, the lower the discriminatory ability of the corresponding biomarker.
Indeed, similar to the Pearson correlation, our measure can be interpreted as an angle between fD and fD¯.
However, since fD > 0 and fD¯ > 0 it follows that 〈fD, fD¯〉 > 0, and thus the angle between fD and fD¯
can only be acute or right, that is fD∠fD¯ is in [0, pi/2], and thus κ¯ is in [0, 1]. Orthogonality between the
biomarker outcome for diseased and non-diseased subjects corresponds to a diagnostic test that perfectly
discriminates between diseased and non-diseased subjects.
However natural the κ¯ in (2) may appear, in practice one may want to avoid the division by the norms—
which in theory could lead to more unstable estimates and constrain us to work with square-integrable
densities—while retaining the main ingredients of the construction above. Since fD and fD¯ are valid
densities, it follows that ‖√fD‖ = ‖
√
fD‖ = 1, and thus we define our summary measure as
κ =
〈√fD,
√
fD¯〉
‖√fD‖‖
√
fD¯‖
= 〈
√
fD,
√
fD¯〉 =
∫ +∞
−∞
√
fD(y)
√
fD¯(y) dy. (3)
Some comments are in order. Similar to (2), orthogonality between the biomarker outcome for diseased
and non-diseased subjects corresponds to the case where the diagnostic test is perfect, that is κ = 0 for a
perfect test—which perfectly discriminates diseased subjects from non-diseased subjects—and κ = 1 for a
useless test—for which fD = fD¯.
3
κ = 1
(AUC = 0.5)
κ = 0.61
(AUC = 0.92)
κ = 0.32
(AUC = 0.98)
−2 −1 0 1 2 3 4 5
0.
0
0.
1
0.
2
0.
3
0.
4
y
D
en
si
ty
−2 −1 0 1 2 3 4 5
0.
0
0.
1
0.
2
0.
3
0.
4
y
D
en
si
ty
−2 −1 0 1 2 3 4 5
0.
0
0.
1
0.
2
0.
3
0.
4
y
D
en
si
ty
(a) (b) (c)
Figure 2: Affinity for Binormal model from Example 1; the black and grey lines respectively denote the densities
of the biomarkers of the diseased and non-diseased subjects; the configurations of parameters are as follows: a)
(µD, σD) = (µD¯, σD¯) = (0, 1); b) (µD, σD) = (2, 1) and (µD¯, σD¯) = (0, 1); c) (µD, σD) = (3, 1) and (µD¯, σD¯) = (0, 1).
Interestingly, the measure κ in (3) is known in mathematical statistics under the name of Hellinger
affinity (van der Vaart, 1998), but we are unaware of applications of the concept in medical diagnostic
statistics. In our context, κ can be interpreted as a measure of the level of agreement between the densities
of the biomarker outcomes for diseased and non-diseased subjects, or equivalently, as a measure of the
highest possible diagnostic test accuracy for a test based on the biomarker.
Example 1 (Binormal affinity). Suppose fD(y) = φ(y | µD, σ2D) and fD¯(y) = φ(y | µD¯, σ2D¯). As stated in
Table 1:
κ =
√
2σDσD¯
σ2D + σ
2
D¯
exp
{
− 1
4
(µD − µD¯)2
σ2D + σ
2
D¯
}
. (4)
As expected, for a useless test—that is µD = µD¯ and σD = σD¯—it holds that κ = 1. For fixed σD > 0
and σD¯ > 0 it follows that as µD → ∞ and µD¯ → −∞, that is as populations become more separated,
then κ→ 0. Indeed, as it can be seen from Figure 2 the more separated the populations—that is the more
orthogonal they are—the closer κ gets to zero. Notice also that, in this setting, the larger the AUC the
lower κ. However, this needs not always be the case, and there are actually situations for which AUC and
κ may recommend different decisions, as will be seen in Examples 2 and 3.
Example 2 (Separation trap). Let’s revisit the setting from Figure 1. The exact setup is{
fD(y) = 1/2φt(y | −6,−4,−5, 1/32) + 1/2φt(y | 4, 6, 5, 1/32),
fD¯(y) = φt(y | −2, 2, 0, 1/42).
Here φt(y | a, b, µ, σ2) is the density of a truncated normal with lower bound a and upper bound b. In this
case it holds that
κ =
∫ ∞
−∞
√
fD(y)
√
fD¯(y) dy
=
∫ −4
−6
√
fD(y)
√
fD¯(y) dy +
∫ 2
−2
√
fD(y)
√
fD¯(y) dy +
∫ 6
4
√
fD(y)
√
fD¯(y) dy = 0.
Thus, κ claims that both populations are perfectly separated—and so it would not fall into the separation
trap.
Table 1 contains two other examples of affinity for parametric models. For completeness we include
derivations of these expressions in the supplementary materials.
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Table 1: Affinity (κ) for bibeta, biexponential, and binormal models; here, λD and λD¯ are the rate parameters of
the corresponding exponential distributions
Model Affinity
Bibeta
B((aD+aD¯)/2,(bD+bD¯)/2)
{B(aD,bD)B(aD¯,bD¯)}1/2
Biexponential
2(λDλD¯)
1/2
λD+λD¯
Binormal
√
2σDσD¯
σ2
D
+σ2
D¯
exp
{
− 1
4
(µD−µD¯)2
σ2
D
+σ2
D¯
}
2.2 Properties and covariate-specific affinity
The following proposition documents two elementary properties associated with our measure of diagnostic
test accuracy.
Proposition 1. Affinity, as defined in (3), obeys the following properties:
1. κ ∈ [0, 1].
2. κ is invariant to monotone increasing data transformations.
A proof of Proposition 1 can be found in the online supplementary materials. Interestingly, just like
affinity, the AUC is also invariant to monotone increasing data transformations (Pepe, 2003). Affinity is also
invariant to whether we work with a test for which larger values of the biomarker are more indicative of dis-
ease, or the other way around; this is an obvious consequence of the fact that 〈√fD,
√
fD¯〉 = 〈
√
fD¯,
√
fD〉.
Thus, for instance, Binormal affinity in (4) is the same, regardless of whether µD > µD¯ or vice versa. For
the lack of better terminology, below we refer to an upper-tailed diagnostic test as one for which larger
values of the biomarker are more indicative of disease, and to a lower-tailed diagnostic test as to one where
larger values of the biomarker are less indicative of disease. Another parallel to the AUC is the fact that
κ can be regarded as an area under a curve, with the curve of interest being
c(y) =
√
fD(y)fD¯(y).
Another interesting aspect is that κ can also be regarded as an average squared likelihood ratio, in the
sense that
κ =
∫ ∞
−∞
√
fD(y)
fD¯(y)
fD¯(y) dy = ED¯
(√
fD(YD¯)
fD¯(YD¯)
)
.
If covariates are available the question arises of how to conduct a covariate-specific analysis for measuring
diagnostic test accuracy using affinity. A natural extension of (3) to the conditional setting is
κ(x) = 〈
√
fD|x,
√
fD¯|x〉 =
∫ +∞
−∞
√
fD(y | x)
√
fD¯(y | x) dy, (5)
where x ∈ X ⊆ Rp is a covariate, fD|x = fD( · | x), and fD¯|x = fD¯( · | x). Below we refer to κ(x) as the
covariate-specific affinity. As with κ, it holds that κ(x) ∈ [0, 1], and that κ(x) is invariant to monotone
increasing data transformations.
Example 3 (Binormal covariate-specific affinity). Extending Example 1, suppose that fD(y | x) = φ(y |
µD(x), σ
2
D(x)) and fD¯(y) = φ(y | µD¯(x), σ2D¯(x)). It then follows that
κ(x) =
√
2σD(x)σD¯(x)
σ2D(x) + σ
2
D¯
(x)
exp
{
− 1
4
{µD(x)− µD¯(x)}2
σ2D(x) + σ
2
D¯
(x)
}
.
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Figure 3: a) Covariate-specific affinity (solid line) for binormal model from Example 3, and corresponding covariate-
specific AUC (dotted line); b) Density of the diseased (black line) and non-diseased (grey line) subjects, for x = 4.
In particular, for µD(x) = x and µD¯(x) = x − 3, and σD(x) = 1 and σD¯(x) = 1 + x2, we obtain the
covariate-specific affinity plotted in Figure 3(a). As it can be observed from Figure 3, for values of the
predictor between 0 and approximately 1.2, both κ and AUC agree that the quality of the test deteriorates
as x increases (κ increases and AUC decreases). As x increases beyond 1.2, each measure suggests a
different conclusion as to how the test accuracy changes with x. To understand the reason for this, we
analyze in further detail the case of x = 4, whose corresponding densities are plotted in Figure 3(b). In the
case x = 4 we have an AUC = 0.504 whereas κ = 0.34. Thus, on the one hand the AUC = 0.504 suggests
that the test is quite poor, whereas the value of κ = 0.34 suggests that it could be satisfactory, though
far from excellent. The intuition underlying this lack of agreement is as follows: κ is taking into account
that around 95% of the mass for the test values for diseased subjects will be on the [0, 8] interval, whereas
around 95% of the mass for the test values of non-diseased subjects will be on the [−30, 38] interval.
2.3 Nonparametric Bayesian inference for affinity and covariate-specific affinity
In this section we discuss Bayesian nonparametric estimators for affinity, as defined in (3), and covariate-
specific affinity, as defined in (5). Let {YD,i}nDi=1 and {YD¯,i}nD¯i=1 be random samples from FD and FD¯. We
propose to estimate κ in (3) by modeling each conditional density fD and fD¯ as an infinite mixture model
of the type
f(y) =
∫
Θ
K(y | θ)G(dθ), (6)
where K is a kernel and G is a random mixing measure. The corresponding induced prior is
κ =
∫ +∞
−∞
{∫
Θ
K(y | θ)GD(dθ)
}1/2{∫
Θ
K(y | θ)GD¯(dθ)
}1/2
dy. (7)
A natural approach is to consider each G as a Dirichlet process (Ferguson, 1973), and to rely on normal
kernels, in which case (6) becomes a so-called Dirichlet process mixture of normal kernels,
f(y) =
∫
R×(0,∞)
φ(y | µ, σ)G(dµ,dσ) =
∞∑
h=1
pihφ(y | µh, σh), G ∼ DP(α,G0). (8)
Here α > 0 is the so-called precision parameter, G0 is the centering distribution function, or baseline
measure, and we use the notation G ∼ DP(α,G0) to represent that G follows a Dirichlet process (DP).
A celebrated representation of the DP is the so-called stick-breaking construction (Sethuraman, 1994).
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According to this representation a random distribution function G follows a DP if it admits a representation
of the type
G =
∞∑
h=1
pihδθh , θh
iid∼ G0, (9)
where pi1 = V1, and pih = Vh
∏
k<h(1 − Vk), with Vh iid∼Beta(1, α), for h = 2, . . . . The θh are known as
atoms, the pih as mixing weights, and the Vh are the so-called stick-breaking weights.
For regression data, {(xi, YD,i)}nDi=1 and {(xi, YD¯,i)}nD¯i=1, we propose to estimate κ(x) in (3) by modeling
each density fD and fD¯ as an infinite mixture model of regressions
f(y | x) =
∫
Θ
K(y | θ)Gx(dθ), (10)
where K is a kernel and Gx is a covariate-specific random mixing measure. The corresponding induced
prior is
κ(x) =
∫ +∞
−∞
{∫
Θ
K(y | θ)GD,x(dθ)
}1/2{∫
Θ
K(y | θ)GD¯,x(dθ)
}1/2
dy. (11)
A natural approach is to consider each Gx as a dependent Dirichlet process (DDP) (MacEachern, 2000),
and to rely on normal kernels in which case (10) becomes an infinite mixture of regression models,
f(y | x) =
∫
R×(0,∞)
φ(y | µ, σ)Gx(dµ, dσ). (12)
Because of the support properties in Theorem 4 of Barrientos et al (2012), we consider a ‘single-weights’
DDP (De Iorio et al , 2004, 2009)
Gx =
∞∑
h=1
pihδθx,h . (13)
The random support locations θx,h are, for h = 1, 2, . . . independent and identically distributed realizations
from a stochastic process over the covariate space X and the weights {pih}∞h=1 match those from a standard
DP; in this specific version of (13) we obtain
f(y | x) =
∞∑
h=1
pihφ(y | µh(x), σh). (14)
To achieve a reasonable tradeoff between flexibility and parsimony, in practice we choose to model µ(x)
as a linear model, that is, µh(x) = x
Tβh, where x
T corresponds to the cubic B-spline basis evaluated
at the predictor. Finally, to facilitate prior specification we suggest standardizing the biomarkers (i.e.,
ZDi = (YDi − Y¯D)/sD and zD¯j = (YD¯j − Y¯D¯)/sD¯) and rescaling the covariate (i.e., min{xD¯, xD} = −1 and
max{xD¯, xD} = 1). Having estimated the densities on the standardized data, the location-scale adjustment
may be applied to easily convert to densities for the untransformed data.
We now present a specific embodiment of our model. Let xT
D¯i
represent the cubic B-spline representation
of xD¯i, with xD¯i having been rescaled to lie in [−1, 1]. The assumptions for the non-diseased population
in the conditional case are that
fD¯(ZD¯i | xD¯i) =
∫
φ(ZD¯i | xTD¯iβ, σ2) dGD¯(β, σ2) (15)
GD¯(β, σ
2) | GD¯0(β, σ2) ∼ DP(1, GD¯0(β, σ2)) (16)
GD¯0(β, σ
2) ≡ N(βD¯0,ΣD¯0)× IG(shape = 1, rate = 50) (17)
βD¯0 ∼ N(0, I) (18)
ΣD¯0 ∼ IWish(ν = 1, S = I), (19)
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where IG and IWish respectively denote the inverse Gamma and inverse Wishart distributions. Two aspects
of this specification are particularly noteworthy. First, it is assumed that the number and locations of all
knots are known, although this could be relaxed. Second, the prior on the within-cluster variance (i.e., σ2)
was chosen to favor variances much less than one. The justification for this is immediate when recognizing
that the likelihood is on standardized data with a marginal sample variance of one; the within-cluster
variance ought to be substantially smaller than the marginal variance. The assumptions are analogous for
the diseased population; the only difference is the substitution of D for D¯. To apply the model specification
without conditioning on any covariate, we can simply substitute xTi = 1.
2.4 Theoretical properties on induced priors
This section includes theoretical properties on the induced priors for the summary measures introduced in
Section 2.1. Although in practice we model the densities from which κ is estimated with a Dirichlet process
mixture, as in (8) and (14), below we document theoretical results which apply more generally to (6) and
(10) and only require that the mixing distribution has a full weak support, which includes the Dirichlet
process as a particular case. In what follows, we assume the same setting as in Lijoi et al (2004), namely:
A1) The random mixing distribution(s) has (have) full weak support.
A2)
∫ +∞
−∞ K(y | θ) dy = 1, for θ ∈ Θ.
A3) θ 7→ K(y | θ) is bounded, continuous, and BΘ-measurable for y ∈ R.
A4) The family of mappings {θ 7→ K(y | θ) : y ∈ C}, is uniformly equicontinuous, for every compact
C ⊂ R.
Here, A1 is a condition on the support of the mixing, whereas A2–A4 are regularity conditions on the
kernel. Under these conditions, it can be shown that f(y) in (6) has full Hellinger support (Lijoi et al ,
2004). As a consequence, the following result holds.
Theorem 1. Suppose A1–A4 and let (Ω,A, P ) be the probability space associated with the infinite mixture
model in (6), which induces κ =
∫ √
fD(y)
√
fD¯(y) dy. Let κ
ω be a realization of the κ index under (6).
Then, for every ε > 0, it holds that P{ω ∈ Ω : |κω − κ| < ε} > 0.
Under the same conditions as above, it can be shown that f(y | x) in (10) has full Hellinger support
(Barrientos et al , 2012). Thus, the following analogous result to Theorem 1 holds for the covariate-specific
version of our summary measure as defined in (5).
Theorem 2. Suppose A1–A4 and let (Ω,A, P ) be the probability space associated with the infinite mixture
of regression models in (10), which induces κ(x) =
∫ √
fD(y | x)
√
fD¯(y | x) dy. Let κω(x) be a trajectory
of covariate-specific affinity κ(x) under (10). Then, for x1, . . . , xn ∈ X , for every positive integer n and
ε > 0, it holds that P{ω ∈ Ω : |κω(xi)− κ(xi)| < ε, i = 1, . . . , n} > 0.
Proofs of Theorems 1 and 2 can be found in the online supplementary materials.
3 Simulation study
3.1 Data generating processes
The simulation settings are summarized in Table 2. The simulation employed pairs of biomarker distribu-
tions that were either conditional on a single uniformly distributed covariate or were unconditional. In the
unconditional settings, each distribution was either normal or a mixture of normals, and the means and
standard deviations were systematically altered so that a range of κ and AUC values were considered. In
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Figure 4: Densities for the second unconditional simulation study setting in Table 2; the black and grey
lines respectively denote the densities of the biomarkers of the diseased and non-diseased subjects.
Table 2: Simulation study settings
Scenario Non-Diseased (fD¯) Diseased (fD) Notes
†
Unconditional #1 φ(.4, .8) φ(µD, σD) 1)
Unconditional #2 .7φ(.1, .2) + .3φ(3.1, .2) .7φ(µ1D, σD) + .3φ(µ2D, σD) 2)
Conditional #1 φ(.5 + xD¯, 1.5) φ(2 + 4xD, 2) 3)
Conditional #2 φ(sin(pi(xD¯ + 1)), .5) φ(.5 + x
2
D, 1) 3)
Conditional #3
φ(sin(pixD¯),
√
.2 + .5 exp(xD¯)) (1 + exp(−x))−1φ(xD, .5) + (1 + exp(x))−1φ(x3D, 1) 3)
†Each unconditional setting has nine distinct pairs of means and variances where for 1): µD in {.8, 1.6, 3.2} and σD in
{.8, 1.2, 1.6} and 2): σD = .2c and (µ1D, µ2D) in {(.2c, 3.2c), (1.1c, 4.1c), (2c, 5c)}, with c in {.6, 1, 1.6}. For the conditional
setting we have 3): xD¯, xD
iid∼ Unif(−1, 1).
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Figure 5: AUC and κ estimates (average across 100 simulations) along with true values in the unconditional scenarios
of the simulation study (Table 2): a) the first unconditional setting (normals); b) the second unconditional setting
(mixtures of normals).
the conditional settings, the conditional distributions were likewise normal or a mixture of normals, and
the covariate’s effect on the mean and standard deviation were altered to have varying levels of complexity.
In terms of the conditional setting, we consider the same scenarios as in Ina´cio de Carvalho et al (2013).
Figure 4 depicts the density pairs from the second unconditional setting; the plots for the remaining
scenarios are included in the supplementary materials. Of particular note is the pattern of possibilities
for κ and AUC when the biomarker densities are mixtures of normals. In particular, the middle plot in
Figure 4 displays a situation where κ is particularly adept at identifying the distinctiveness of the diseased
and non-diseased populations as can be seen by the very small κ value. However, our convention that
AUC be computed assuming the diagnostic test will be one-sided forces the AUC to be lower than might
be expected given the distinctiveness of the populations. While it is certainly possible to entertain more
flexible regions at which the diagnostic test would be considered to have a positive result, this would require
another nontrivial step before AUC could even be calculated, whereas such a step is not needed to calculate
κ.
3.2 Monte Carlo simulation study
For each setting in Table 2, we generated 100 data sets from fD and from fD¯. The sample sizes were
varied at nD = nD¯ = 150, 500, or 2000 to provide some sense of how reliably κ and AUC were estimated in
moderate to large samples. In implementing the model, detailed in (15), no additional knots for the cubic
B-splines were included; this lets us ascertain the covariate-dependent model’s flexibility in the absence of
extra knots. Additionally, because the covariate values were simulated from the Unif(-1,1) distribution, we
did not rescale the covariate prior to computing the B-spline representation. For each synthetic data set
κ was estimated by collecting 300 MCMC iterates after a burn in of 2000 and thinning of 40. Algorithm 8
of Neal (2000) was employed to collect the iterates.
The results from the unconditional settings are summarized in Figure 5, which depicts the Monte Carlo
average (across 100 simulations) of the estimated values for κ and AUC, along with the actual values. In
part a), which was characterized by each population having a normal distribution, κ and AUC were both
estimated with little bias. Not surprisingly, the bias is reduced by having larger sample sizes. In part b),
which was characterized by each population having a mixture of normals distribution, the same pattern
was exhibited.
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Figure 6: Estimated covariate-specific affinity, κ(x), and covariate-specific AUC, AUC(x), across the 100 simulated
data sets for the conditional settings described in Table 2. The bands represent the pointwise empirical 2.5th and
97.5th percentiles of the 100 point estimates, while the dark grey lines represent the average of the 100 estimates.
The results from the conditional settings are summarized in Figure 6. For each of the 100 simulated
data sets, the conditional means for κ and AUC were estimated at values of x ranging from -1 to 1. The
pointwise averages of the 100 estimated means are plotted in this figure, as well as the 2.5th and 97.5th
empirical percentiles of these estimated means. This gives some sense for how variable the estimates are
(primarily attributable to differences between the 100 simulated data sets). Point estimates of AUC(x) and
κ(x) were quite successful in estimating the corresponding true values. Predictably, the estimates exhibited
less variability as more data were available. Recall that a strength of κ(x) is that it is not susceptible to
the separation trap, nor does it require us to distinguish between upper- and lower-tailed diagnostic tests.
This distinction for AUC(x) explains why the AUC is sometimes estimated to be well below 0.5. Given
these advantages of κ(x) over AUC(x), it is even more notable that κ(x) can be reliably estimated. An
important collateral suggestion of the simulation is that the model is quite flexible even if the cubic B-spline
basis does not include additional knots, though of course knots may be added if desired.
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4 Revisiting a prostate cancer diagnosis study
We now turn our attention to an application that has been regularly employed to demonstrate diagnostic
test accuracy that is covariate-dependent.
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Figure 7: Top: DPM-based estimated densities along with AUC and κ values when age is not considered. The black
and grey lines respectively denote the densities of the biomarkers of the diseased and non-diseased subjects. Bottom:
Overlapping histograms.
4.1 Study data and preliminary considerations
The data were gathered from the Beta-Carotene and Retinol Efficacy Trial (CARET)—a lung cancer
prevention trial, conducted at the Fred Hutchinson Cancer Research Center. During this study longitudinal
measurements of two Prostate Specific Antigen (PSA)-based biomarkers were collected for 71 prostate
cancer cases and 70 controls. The biomarker measurements were taken on males between 46 and 80 years
old. The number of repeated measures per subject ranged from one to nine, with n = 683 total observations.
Further details on this study can be found, for instance, in Etzioni et al (1999) and Pepe (2003). To make
our inferences directly comparable with those of Rodriguez and Martinez (2014)—who consider a Gaussian
process prior-based model for AUC(x)—we follow the latter authors and ignore the longitudinal nature of
the data; however, for reference, we also include in the supplementary materials the results from restricting
analysis to each subject’s last available observation. A test based on total PSA concentration (Biomarker 1,
ng/ml) was assumed to have a positive test result if the measurement was sufficiently large. Conversely, a
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test based on the free-to-total PSA ratio (Biomarker 2, f/t) was assumed to have a positive test result if
the measurement was sufficiently small.
The direction of the tendency is of no consequence in estimating κ. In estimating AUC, however, we
must consider the direction of the diagnostic test, that is whether larger values of the biomarker are more
indicative of disease or the other way around. A main goal below will be on illustrating how the proposed
methods can be used to assess which biomarker might screen better for prostate cancer.
4.2 PSA-based analysis
We first fit the unconditional model (i.e., sans covariate so that xTi = 1) detailed in (15) by collecting
1 800 MCMC iterates after a burn in of 20 000 and thinning of 100. To visualize differences between the
biomarkers we provide Figure 7. For each biomarker, the estimated density among cases and controls are
superimposed. It is readily apparent that there are differences between cases and controls, and that the
direction of the differences depends on which biomarker we consider. Both univariate summaries, κ and
AUC, signal a preference for the first biomarker as a screening mechanism. The 95% credible interval of κ
associated with Biomarker 1 is (0.71, 0.77) and for AUC is (0.80, 0.86), while for Biomarker 2 the interval
for κ is (0.83, 0.90) and for AUC (0.70, 0.77) respectively.
On the one hand, total PSA (Biomarker 1) looks like a reasonable biomarker since AUC = 0.83, but on
the other hand κ seems to be putting into question that evidence (κ = 0.74). The overlapping histograms
in Figure 7 shed some light on the reasons underlying the lack of consensus between AUC and κ. Despite
the fact that the AUC is moderately large in both cases, there is a considerable overlap between the
distributions of the biomarkers for diseased and non-diseased subjects. And interestingly, the modes of
both distributions are not that far apart. But perhaps this should not be regarded surprising since the
discrimination power of PSA has been called into question and often regarded as controversial (Prensner
et al , 2012; Harvard, 2017).
4.3 PSA-based analysis with age-adjustment
It is well known that PSA levels may be age-dependent—for both diseased and non-diseased subjects—since
both benign prostate conditions and prostate cancer become more common with age. With this in mind,
we obtained conditional density estimates for each biomarker in each population to estimate κ(age) and
AUC(age) by fitting the conditional model and collecting 1 800 MCMC iterates after a burn in of 20 000
and thinning of 100 and using the same specifications as before. In model fitting, the patients’ ages were
first rescaled from the interval [46.75, 80.83] to the interval [−1, 1], and, following numerical evidence from
Ina´cio de Carvalho et al (2017, Section 3), we elected to not to include any additional knots in the cubic
B-splines.
Figure 8 displays the posterior mean and pointwise 95% credible intervals for κ and AUC as a function
of age. Notice first that for Biomarker 1 our estimated AUC(age) is very similar to that found in Figure 4
of Rodriguez and Martinez (2014), with the largest discriminatory power occurring when an individual is
in their late 50s. Regarding comparisons with κ, generally speaking Biomarker 1 exhibits less affinity than
Biomarker 2 between the distributions of those with and without a prostate cancer diagnosis. This suggests
that a diagnostic test based on Biomarker 1 would be preferred to a test based on Biomarker 2. The first
biomarker’s affinity appears to be sensitive to the subject’s age. In line with the findings in the previous
section, AUC seems to indicate that PSA is a reasonably good diagnostic test, while κ seems to be more
pessimistic regarding the test’s ability (κ ≈ 0.6); a similar conclusion holds for Biomarker 2. In addition,
κ more clearly identifies the difference in screening ability of the two biomarkers for males aged 55 to 70.
Furthermore, it is invariant to whether the diagnostic test is assumed to be lower- or upper-tailed. Finally,
both analyses suggest Biomarker 1 is a better alternative than Biomarker 2 in screening older males with
lung cancer for prostate cancer. This latter conclusion is supported even more emphatically by κ(age) than
by AUC(age), as seen in Figure 8.
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Figure 8: Means and 95% pointwise credible intervals for the age-adjusted affinity and AUC of two biomarkers in
cases and controls. a) is the age-adjusted affinity; b) is the age-adjusted AUC if both biomarkers have upper-tailed
diagnostic tests; c) is the age-adjusted AUC if the second biomarker diagnostic test is lower-tailed. In each panel,
the black and grey lines respectively denote the first and second biomarkers.
5 Discussion
In this paper we show how Hellinger affinity can be used as a natural summary measure of medical
diagnostic accuracy. The summary measure has several desirable properties that motivate its use as a
supplement, if not competitor, to other existing summaries such as AUC and the Youden index. Affinity
shares some of the properties of the AUC—such as invariance to monotone increasing transformations—,
but it does not fall into the separation trap, whereas both the AUC and the Youden index would. Indeed,
a principal advantage of κ is that it is readily calculated and interpreted without assuming anything about
the biomarker threshold(s) that demarcate positive and negative test diagnoses. This can be especially
beneficial if, for instance, a biomarker’s distribution when the disease is present favors both atypically low
and atypically high values. Affinity-based measures can be framed into the same geometrical principles as
Pearson correlation, and they focus on the overlap between fD and fD¯ rather than on always presuming
that larger values of a biomarker are more indicative of disease. Nonparametric Bayes estimators for
affinity and covariate-specific affinity are discussed, and theoretical properties of the corresponding priors
have been derived. While it could be natural to fit parametric models such as the ones in Table 1, the
added flexibility of the proposed inferences allows us to model diagnostic test accuracy in a way that offers
flexibility and robustness against misspecification.
While not explored here, our summary measure has the potential to be applied to the more general
setting where p > 1 biomarkers per subject are available. Indeed, if fD(y) and fD¯(y) denote the joint
distributions of the p biomarkers, for diseased and non-diseased subjects, similarly to (3) one can define
κ = 〈
√
fD,
√
fD¯〉 =
∫
Rp
√
fD(y)
√
fD¯(y) dy.
However, estimation of κ would become more challenging in the multivariate case than in the univariate case
presented in this article. Future work could also entail nonparametric Bayesian inference for a covariate-
specific version of the so-called overlap coefficient (Wang and Tian, 2017) which can be defined as
OVL(x) =
∫ ∞
−∞
min{fD(y | x), fD¯(y | x)} dy.
The index in (5) would quantify the proportion of overlap area between fD(y | x) and fD¯(y | x), and thus
it could be used as a companion to AUC(x) and κ(x). Finally, another direction which we may revisit in
future work rests on the study of κ(x) and OVL(x) on settings where a gold standard test is unavailable.
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§1. Properties of affinity
§1.1. Proof of Proposition 1
The proof is as follows:
1. Since
√
fD(y) > 0 and
√
fD¯(y) > 0 it follows that κ > 0. Cauchy–Schwarz inequality further implies
that |κ| = 〈√fD,
√
fD¯〉 6 ‖
√
fD‖‖
√
fD¯‖ = 1.
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2. The argument is tantamount to that of Roos and Held (2011), but it is included here for completeness.
Let g(y) = z be a monotone increasing function and let
fgD(z) = fD(g
−1(z))
d
dz
g−1(z), fg
D¯
(z) = fD¯(g
−1(z))
d
dz
g−1(z),
be densities of the transformed data g(YD) and g(YD¯) (Knight, 2000), and denote by κ
g = 〈
√
fgD,
√
fg
D¯
〉
the affinity of the transformed data. It thus follows that
κg =
∫ ∞
−∞
√
fgD(z)
√
fg
D¯
(z) dz
=
∫ ∞
−∞
{
fD(g
−1(z))
d
dz
g−1(z)
}1/2{
fD¯(g
−1(z))
d
dz
g−1(z)
}1/2
dz
=
∫ ∞
−∞
√
fD(g−1(z))
√
fD¯(g
−1(z))
d
dz
g−1(z) dz (set g−1(z) = y)
=
∫ ∞
−∞
√
fD(y)
√
fD¯(y) dy = κ.
§2. Properties of induced priors
§2.1. Proof of Theorem 1
The proof involves some manipulations similar to those often used for showing continuity of the inner
product (Hunter and Nachtergaele, 2001), along with a result from Lijoi et al (2004). Just note that
|κω − κ| = |〈√fωD,√fωD¯〉 − 〈√fD,√fD¯〉|
= |〈√fωD,√fωD¯〉 − 〈√fωD,√fD¯〉+ 〈√fωD,√fD¯〉 − 〈√fD,√fD¯〉|
6 |〈√fωD,√fωD¯〉 − 〈√fωD,√fD¯〉|+ |〈√fωD,√fD¯〉 − 〈√fD,√fD¯〉|
6 |〈√fωD,√fωD¯ −√fD¯〉|+ |〈√fωD −√fD,√fD¯〉|
6 ‖√fωD‖︸ ︷︷ ︸
1
‖
√
fω
D¯
−
√
fD¯‖+ ‖
√
fωD −
√
fD‖ ‖
√
fD¯‖︸ ︷︷ ︸
1
=
√
dH(fωD¯, fD¯) +
√
dH(fωD, fD),
(20)
where dH(f, g) =
∫ {√f(y)−√g(y)}2 dy is the Hellinger distance. So, as it can be seen from (20), to have
|κω − κ| < ε, with ε > 0, it would suffice having dH(fωD¯, fD¯) < ε2/4 and dH(fωD, fD) < ε2/4. Thus,
{ω ∈ Ω : |κω − κ| < ε} ⊇ {ω ∈ Ω : dH(fωD¯, fD¯) < ε2/4, dH(fωD, fD) < ε2/4},
from where it finally follows that
P{ω ∈ Ω : |κω − κ| < ε} > P{ω ∈ Ω : dH(fωD¯, fD¯) < ε2/4}︸ ︷︷ ︸
piD¯
P{ω ∈ Ω : dH(fωD, fD) < ε2/4}︸ ︷︷ ︸
piD
> 0,
given that from the equivalence between Hellinger and L1 support, and from Section 3 in Lijoi et al (2004)
it follows that piD¯ > 0 and piD > 0.
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§2.2. Proof of Theorem 2
The proof is along the same lines as that of Theorem 1 but it requires Theorem 4 of Barrientos et al
(2012), which is essentially a covariate-specific version of the result in Section 3 of Lijoi et al (2004).
Similar derivations as those in (20) yield
|κω(xi)− κ(xi)| 6
√
dH(fωD¯|xi , fD¯|xi) +
√
dH(fωD|xi , fD|xi).
Hence, to have |κω(xi)− κ(xi)| < ε, for ε > 0, it would suffice having
dH(f
ω
D¯|xi , fD¯|xi) < ε
2/4, dH(f
ω
D|xi , fD|xi) < ε
2/4, i = 1, . . . , n,
and thus using similar arguments to the ones in proof of Theorem 1 it follows that
P{ω ∈ Ω : |κω(xi)− κ(xi)| < ε} > P{ω ∈ Ω : dH(fωD¯|xi , fD¯|xi) < ε
2/4, i = 1, . . . , n}︸ ︷︷ ︸
piD¯
× P{ω ∈ Ω : dH(fωD|xi , fD|xi) < ε2/4, i = 1, . . . , n}︸ ︷︷ ︸
piD
> 0,
given that Theorem 4 of Barrientos et al (2012), on the Hellinger support of the DDP, implies that piD¯ > 0
and piD > 0.
§3. Simulation setting figures
Because of limited space in the article, only the second unconditional setting (70/30 mixtures of normals)
from the simulation study was illustrated with a figure. We therefore include Figure 9 to display the
densities, κs, and AUCs from the first unconditional setting of Table 2. We also had included three
covariate-dependent settings. Due to the challenges inherent in overlaying bivariate densities, we do not
display the densities for the three conditional settings of Table 2, instead displaying only κ(x) and AUC(x).
These covariate-dependent quantities are plotted in Figure 10.
§4. Additional empirical reports
In the PSA data application (as reported in the article), the analysis proceeded as though 683 independent
measures were obtained. This was done to enable comparison with an existing analysis of this data set by
Rodriguez and Martinez (2014). One natural alternative is to use only the last available observation from
each of the n = 141 subjects. We made this restriction and repeated the analyses. In doing so, the range
of observed ages was slightly reduced from [46.75, 80.83]—the range with the 683 observations—to [51.94,
80.83]. To apply the model in light of this smaller age range, the ages were rescaled so that 51.94 became
x = −1 and 80.83 became x = 1.
The results from the unconditional and age-dependent analyses are contained in Figure 11 and Figure 12,
respectively. The results when restricting the data to the last available observations are rather similar to
the results when ignoring the dependence among all 683 observations. However, not only is there more
uncertainty in the affinity and AUC estimates, but the estimates of both κ and AUC are slightly more
favorable with the 141 observations than they were with the 683 observations. This might be due to the
fact that the last available observations on the PSA biomarkers were the closest observations to the time
of diagnosis.
18
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.97
AUC=0.64
D
en
si
ty
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.94
AUC=0.61
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.88
AUC=0.59
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.75
AUC=0.86
D
en
si
ty
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.81
AUC=0.80
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.80
AUC=0.75
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.22
AUC=0.99
D
en
si
ty
y
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.37
AUC=0.97
y
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
κ = 0.48
AUC=0.94
y
Figure 9: Densities for the first unconditional simulation study setting in Table 2 of the article; the black
and grey lines respectively denote the densities of the biomarkers of the diseased and non-diseased subjects.
−1.0 −0.5 0.0 0.5 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Conditional Setting 1
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
AU
C(
x)
x
κ
(x)
κ(x)
AUC(x)
−1.0 −0.5 0.0 0.5 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Conditional Setting 2
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
AU
C(
x)
x
κ
(x)
κ(x)
AUC(x)
−1.0 −0.5 0.0 0.5 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Conditional Setting 3
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
AU
C(
x)
x
κ
(x)
κ(x)
AUC(x)
Figure 10: Covariate-dependent affinity and AUC for the three conditional settings in Table 2 of the
article; the black and grey lines respectively denote κ(x) and AUC(x).
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Figure 11: Last available observation analysis I; this figures compares with Fig. 7 on the manuscript. Top:
DPM-based estimated densities along with AUC and κ values when age is not considered. The black and
grey lines respectively denote the densities of the biomarkers of the diseased and non-diseased subjects.
Bottom: Overlapping histograms.
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Figure 12: Last available observation analysis II; this figures compares with Fig. 8. Means and 95%
pointwise credible intervals for the age-adjusted affinity and AUC of two biomarkers in cases and controls.
Only the last available observation per subject was considered. a) is the age-adjusted affinity; b) is the
age-adjusted AUC if both biomarkers have upper-tailed diagnostic tests; c) is the age-adjusted AUC if the
second biomarker diagnostic test is lower-tailed. In each panel, the black and grey lines respectively denote
the first and second biomarkers.
20
§5. Analytical derivations of entries in Table 1
Bibeta
Let YD ∼ Beta(aD, bD) and YD¯ ∼ Beta(aD¯, bD¯). Then,
κ =
∫ +∞
−∞
√
fD(y)
√
fD¯(y) dy
=
∫ 1
0
{
yaD−1(1− y)bD−1
B(aD, bD)
}1/2{yaD¯−1(1− y)bD¯−1
B(aD¯, bD¯)
}1/2
dy
=
∫ 1
0 y
(aD+aD¯)/2−1(1− y)(bD+bD¯)/2−1 dy
{B(aD, bD)B(aD¯, bD¯)}1/2
=
B((aD + aD¯)/2, (bD + bD¯)/2)
{B(aD, bD)B(aD¯, bD¯)}1/2
,
where B(a, b) =
∫ 1
0 u
a−1(1− u)b−1 du.
Biexponential
Let YD ∼ Exp(λD) and YD¯ ∼ Exp(λD¯). Then,
κ =
∫ +∞
−∞
√
fD(y)
√
fD¯(y) dy =
∫ +∞
0
√
λD exp{−λDy}
√
λD¯ exp{−λD¯y}) dy
= (λDλD¯)
1/2
∫ +∞
0
exp
{
− λD + λD¯
2
y
}
dy =
2(λDλD¯)
1/2
λD + λD¯
.
Binormal
Let YD ∼ N(µD, σD) and YD¯ ∼ N(µD¯, σD¯). Then,
κ =
∫ +∞
−∞
√
fD(y)
√
fD¯(y) dy
=
∫ +∞
−∞
[
(2piσ2D)
−1/2 exp
{
− 1
2
(y − µD)2
σ2D
}]1/2[
(2piσ2D¯)
−1/2 exp
{
− 1
2
(y − µD¯)2
σ2
D¯
}]1/2
dy
=
1√
2piσDσD¯
∫ +∞
−∞
exp
{
− 1
4
(
(y − µD)2
σ2D
+
(y − µD¯)2
σ2
D¯
)}
dy
=
1√
2piσDσD¯
∫ +∞
−∞
exp
{
− 1
4σ2Dσ
2
D¯
(
(σ2D + σ
2
D¯)y
2 − 2(σ2D¯µD + σ2DµD¯)y + σ2D¯µ2D + σ2Dµ2D¯
)}
dy
=
1√
2piσDσD¯
exp
{
− 1
4σ2Dσ
2
D¯
(
σ2D¯µ
2
D + σ
2
Dµ
2
D¯ −
(σ2
D¯
µD + σ
2
DµD¯)
2
σ2
D¯
+ σ2D
)}
×
∫ +∞
−∞
exp
{
− 1
2(2σ2Dσ
2
D¯
/(σ2D + σ
2
D¯
))
(
y −
(
σ2
D¯
µD + σ
2
DµD¯
σ2
D¯
+ σ2D
))2}
dy
=
1√
2piσDσD¯
√
2pi
2σ2Dσ
2
D¯
σ2D + σ
2
D¯
exp
{
− 1
4σ2Dσ
2
D¯
(
σ2D¯µ
2
D + σ
2
Dµ
2
D¯ −
(σ2
D¯
µD + σ
2
DµD¯)
2
σ2
D¯
+ σ2D
)}
=
√
2σDσD¯
σ2D + σ
2
D¯
exp
{
− 1
4
(µD − µD¯)2
σ2D + σ
2
D¯
}
.
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